Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

J. W. C. Alffenaar; T. van der Laan; S. Simons; T. S. van der Werf; P. J. van de Kasteele; H. de Neeling; D. van Soolingen

doi:10.1128/AAC.01297-10

Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

J. W. C. Alffenaar^*
, T. van der Laan
, S. Simons
, T. S. van der Werf
, P. J. van de Kasteele
, H. de Neeling
, D. van Soolingen

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Article › Academic › peer-review

68 Citations (Scopus)

Abstract

Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Original language	English
Pages (from-to)	1287-1289
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	55
Issue number	3
DOIs	https://doi.org/10.1128/AAC.01297-10
Publication status	Published - Mar-2011

Keywords

MULTIDRUG-RESISTANT TUBERCULOSIS
MITOCHONDRIAL PROTEIN-SYNTHESIS
MURINE MODEL
OXAZOLIDINONES
PHARMACOKINETICS
TOLERABILITY
INHIBITION
EFFICACY
DRUGS

Access to Document

10.1128/AAC.01297-10

Handle.net

Persistent link

Cite this

@article{e5b171472fda48ae8ee5bf8cfba35ff7,

title = "Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480",

abstract = "Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).",

keywords = "MULTIDRUG-RESISTANT TUBERCULOSIS, MITOCHONDRIAL PROTEIN-SYNTHESIS, MURINE MODEL, OXAZOLIDINONES, PHARMACOKINETICS, TOLERABILITY, INHIBITION, EFFICACY, DRUGS",

author = "Alffenaar, \{J. W. C.\} and \{van der Laan\}, T. and S. Simons and \{van der Werf\}, \{T. S.\} and \{van de Kasteele\}, \{P. J.\} and \{de Neeling\}, H. and \{van Soolingen\}, D.",

year = "2011",

month = mar,

doi = "10.1128/AAC.01297-10",

language = "English",

volume = "55",

pages = "1287--1289",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "AMER SOC MICROBIOLOGY",

number = "3",

}

TY - JOUR

T1 - Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

AU - Alffenaar, J. W. C.

AU - van der Laan, T.

AU - Simons, S.

AU - van der Werf, T. S.

AU - van de Kasteele, P. J.

AU - de Neeling, H.

AU - van Soolingen, D.

PY - 2011/3

Y1 - 2011/3

N2 - Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).

AB - Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).

KW - MULTIDRUG-RESISTANT TUBERCULOSIS

KW - MITOCHONDRIAL PROTEIN-SYNTHESIS

KW - MURINE MODEL

KW - OXAZOLIDINONES

KW - PHARMACOKINETICS

KW - TOLERABILITY

KW - INHIBITION

KW - EFFICACY

KW - DRUGS

U2 - 10.1128/AAC.01297-10

DO - 10.1128/AAC.01297-10

M3 - Article

SN - 0066-4804

VL - 55

SP - 1287

EP - 1289

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this